ArticleScientific reports2025
Hemoglobinopathies and iron deficiency among Northeast-Thai blood donors deferred for low hemoglobin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While iron deficiency (ID) is well-known as the main reason for low hemoglobin (Hb) deferral among blood donors, the contribution of hemoglobinopathies (HgPs) has been overlooked. This study determines the prevalence of HgPs and ID among northeast (NE) Thai blood donors deferred for low Hb and investigates factors associated with ID. Participation included a total of 355 blood donors that were deferred for low Hb. A self-administered questionnaire was used to collect sociodemographic and health-related information. HgPs and ID were diagnosed following standard guidelines. The prevalence of HgPs and ID was 72.1% (95% CI = 67.1–76.7) and 31.0% (95% CI = 26.2–36.1), respectively. Of the HgP carriers, Hb E and its interaction with α-thalassemia were most common. All forms of HgPs and the use of iron supplement showed a reduction in the odds of having ID, as compared to the reference group. The lowest chance of having an ID was observed in individuals homozygous for Hb E with an adjusted OR (aOR) of 0.04 (95% CI = 0.005–0.31). The odds of having ID among females was 12.4 times (95% CI = 1.5-102.6) higher than males. The findings indicate that HgPs predominate over ID among NE-Thai blood donors deferred for low Hb, and carriers of HgPs are less likely to develop ID than non-HgPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.